Patents by Inventor Stacie Canan Koch

Stacie Canan Koch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20070021354
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 9, 2006
    Publication date: January 25, 2007
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • Tricyclic inhibitors of poly(ADP-ribose) polymerases
    Publication number: 20060009517
    Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Application
    Filed: September 6, 2005
    Publication date: January 12, 2006
    Inventors: Stephen Webber, Stacie Canan-Koch, Jayashree Tikhe, Lars Thoresen
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20050250707
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 10, 2005
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20050124683
    Abstract: The present invention relates to a series of chemical compounds useful as Human Immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents.
    Type: Application
    Filed: September 16, 2004
    Publication date: June 9, 2005
    Inventors: Larry Alegria, Stacie Canan-Koch, Klaus Dress, Buwen Huang, Robert Kumpf, Kathleen Lewis, Jean Matthews, Sylvie Sakata, Scott Virgil
  • Tricyclic inhibitors of poly(ADP-ribose) polymerases
    Publication number: 20050085460
    Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Application
    Filed: December 3, 2004
    Publication date: April 21, 2005
    Inventors: Stephen Webber, Stacie Canan-Koch, Jayashree Tikhe, Lars Thoresen
  • Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
    Publication number: 20040248879
    Abstract: Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Application
    Filed: March 29, 2004
    Publication date: December 9, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie Canan-Koch, Jan-Jon Chu, Jia Liu, Jean Matthews
  • Dimer-selective RXR modulators and methods for their use
    Publication number: 20040019072
    Abstract: Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.
    Type: Application
    Filed: February 5, 2003
    Publication date: January 29, 2004
    Inventors: Stacie Canan-Koch, Chan K. Hwang, Marcus F. Boehm, Beth Ann Badea, Laura J. Dardashti, Lin Zhang, Alex M. Nadzan, Richard A. Heyman, Ranjan Mukherjee, Deepak S. Lala, Luc J. Farmer
  • Dimer-selective RXR modulators and methods for their use
    Patent number: 6545049
    Abstract: Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: April 8, 2003
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Stacie Canan-Koch, Chan K. Hwang, Marcus F. Boehm, Beth Ann Badea, Laura J. Dardashti, Lin Zhang, Alex M. Nadzan, Richard A. Heyman, Ranjan Mukherjee, Deepak S. Lala, Luc J. Farmer
  • Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
    Patent number: 6320074
    Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: November 20, 2001
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Marcus F. Boehm, Richard A. Heyman, Lin Zhi, Stacie Canan Koch